Alphamab Oncology (HKG:9966)
Hong Kong
· Delayed Price · Currency is HKD 8.59
+0.58 (7.24%)
Mar 10, 2026, 1:30 PM HKT
Alphamab Oncology Revenue
Alphamab Oncology had revenue of 319.44M CNY in the half year ending June 30, 2025, with 134.08% growth. This brings the company's revenue in the last twelve months to 785.96M, up 207.17% year-over-year. In the year 2024, Alphamab Oncology had annual revenue of 640.08M with 192.58% growth.
Revenue (ttm)
785.96M CNY
Revenue Growth
+207.17%
P/S Ratio
9.01
Revenue / Employee
1.62M CNY
Employees
484
Market Cap
7.76B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.49B |
| Lepu Biopharma | 767.54M |
| Abbisko Cayman | 681.17M |
| CARsgen Therapeutics Holdings | 139.84M |
| CStone Pharmaceuticals | 221.89M |
| Shanghai Haohai Biological Technology | 2.75B |
| HBM Holdings | 908.35M |
| Ocumension Therapeutics | 595.79M |
Alphamab Oncology News
- 2 months ago - Alphamab Oncology's JSKN033 Cleared For Phase 2 Cervical Cancer Trial By Chinese Regulatory Agency - Nasdaq